623579-03-3

Basic information

• Product Name: (2S,3R)-rel-1-Methyl-2-(3-pyridinyl)-3-pyrrolidinemethanamine
• Synonyms: (2S,3R)-rel-1-Methyl-2-(3-pyridinyl)-3-pyrrolidinemethanamine;rac-trans 3’-Aminomethyl Nicotine;rac-trans 3a€-Aminomethyl Nicotine
• CAS NO: 623579-03-3
• Molecular Formula: C11H17N3
• Molecular Weight: 191.27278
• Product Categories: Amines;Heterocycles;Nicotine Derivatives;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 623579-03-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: (2S,3R)-rel-1-Methyl-2-(3-pyridinyl)-3-pyrrolidinemethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R)-rel-1-Methyl-2-(3-pyridinyl)-3-pyrrolidinemethanamine(623579-03-3)
• EPA Substance Registry System: (2S,3R)-rel-1-Methyl-2-(3-pyridinyl)-3-pyrrolidinemethanamine(623579-03-3)

Safety Data

• Hazardous Substances Data: 623579-03-3(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Oil

Uses

Different sources of media describe the Uses of 623579-03-3 differently. You can refer to the following data:
1. A nicotine conjugate for therapy of nicotine addiction.
2. A Nicotine (N412420) conjugate for therapy of nicotine addiction.

Upstream product

• 939437-34-0 (±)-trans-1-methyl-5-oxo-2-(pyridin-3-yl)pyrrolidine-3-carboxamide 

Downstream Products

• 272124-60-4 (-)-((2S,3R)-1-methyl-2-(pyridin-3-yl)pyrrolidin-3-yl)methanamine 

Relevant articles and documents

A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity

A leading nicotine conjugate vaccine was only efficacious for one-third of clinical trial participants, likely due in part to its use of racemic nicotine hapten, (±)-3′-AmNic. Immunization of male Wistar rats with (+)-, (-)-, or (±)-3′-AmNicSucTT and subsequent antibody immunoassays suggest that a vaccine using enantiopure (-)-3′-AmNic hapten imparts superior capacity to bind (-)-nicotine. Future nicotine vaccine clinical candidates must incorporate this design consideration (i.e., hapten enantiopurity) in order to maximize efficacy.